Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

KCNH2A561V Heterozygous Mutation Inhibits KCNH2 Protein Expression via The Activation of UPR Mediated by ATF6

B. Chen, L. Tan, D. Chen, X. Wang, J. Liu, X. Huang, Y. Wang, S. Huang, F. Mao, J. Lian

. 2023 ; 72 (5) : 621-631. [pub] 2023Nov28

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23020558

The potassium channel protein KCNH2 is encoded by KCNH2 gene, and there are more than 300 mutations of KCNH2. Unfolded protein response (UPR) is typically initiated in response to an accumulation of unfolded and/or misfolded proteins in the endoplasmic reticulum (ER). The present study aimed to explore the UPR process and the role of activating transcription factor 6 (ATF6) in the abnormal expression of potassium voltage-gated channel subfamily H member 2 (KCNH2)A561V. The wild-type (wt) KCNH2 and A561V mutant KCNH2 was constructed with his-tag. The 293 cells were used and divided into KCNH2wt+KCNH2A561V, KCNH2wt and KCNH2A561V groups. The expression levels of ATF6 and KCNH2 in different groups were detected by Western blotting, reverse transcription-quantitative PCR, immunofluorescence and immuno-coprecipitation assays. The protein types and abundance of immuno-coprecipitation samples were analyzed by mass spectrometry. The proteomic analysis of the mass spectrometry results was carried out by using the reactome database and GO (Gene Ontology) tool. The mRNA expression levels of KCNH2 and ATF6 in the KCNH2wt+KCNH2A561V group were higher compared with the KCNH2A561V group. However, the full-length protein expression of ATF6 was inhibited, indicating that ATF6 was highly activated and a substantial number of ATF6 was sheared in KCNH2wt+KCNH2A561V group compared with control group. Furthermore, A561V-KCNH2 mutation leading to the accumulation of the immature form of KCNH2 (135 kDa bands) in ER, resulting in the reduction of the ratio of 155 kDa/135 kDa. In addition, the abundance of UPR-related proteins in the KCNH2A561V group was higher compared with the KCNH2wt+KCNH2A561V group. The 'cysteine biosynthetic activity' of GO:0019344 process and the 'positive regulation of cytoplasmic translation activity' of GO:2000767 process in the KCNH2A561V group were higher compared with the KCNH2wt+KCNH2A561V group. Hence, co-expression of wild-type and A561V mutant KCNH2 in 293 cells activated the UPR process, which led to the inhibition of protein translation and synthesis, in turn inhibiting the expression of KCNH2. These results provided a theoretical basis for clinical treatment of Long QT syndrome.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23020558
003      
CZ-PrNML
005      
20250502124232.0
007      
ta
008      
231215s2023 xr f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.935095 $2 doi
035    __
$a (PubMed)38015761
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Chen, B. $u Emergency Medical Center, Ningbo Yinzhou No. 2 Hospital, Ningbo, Zhejiang, China; Department of General Surgery, Ningbo No.2 Hospital, Ningbo, China. 103875411@qq.com; Department of Cardiology, Ningbo Medical Center LiHuiLi Hospital, Ningbo, China. hjmpin@163.com
245    10
$a KCNH2A561V Heterozygous Mutation Inhibits KCNH2 Protein Expression via The Activation of UPR Mediated by ATF6 / $c B. Chen, L. Tan, D. Chen, X. Wang, J. Liu, X. Huang, Y. Wang, S. Huang, F. Mao, J. Lian
520    9_
$a The potassium channel protein KCNH2 is encoded by KCNH2 gene, and there are more than 300 mutations of KCNH2. Unfolded protein response (UPR) is typically initiated in response to an accumulation of unfolded and/or misfolded proteins in the endoplasmic reticulum (ER). The present study aimed to explore the UPR process and the role of activating transcription factor 6 (ATF6) in the abnormal expression of potassium voltage-gated channel subfamily H member 2 (KCNH2)A561V. The wild-type (wt) KCNH2 and A561V mutant KCNH2 was constructed with his-tag. The 293 cells were used and divided into KCNH2wt+KCNH2A561V, KCNH2wt and KCNH2A561V groups. The expression levels of ATF6 and KCNH2 in different groups were detected by Western blotting, reverse transcription-quantitative PCR, immunofluorescence and immuno-coprecipitation assays. The protein types and abundance of immuno-coprecipitation samples were analyzed by mass spectrometry. The proteomic analysis of the mass spectrometry results was carried out by using the reactome database and GO (Gene Ontology) tool. The mRNA expression levels of KCNH2 and ATF6 in the KCNH2wt+KCNH2A561V group were higher compared with the KCNH2A561V group. However, the full-length protein expression of ATF6 was inhibited, indicating that ATF6 was highly activated and a substantial number of ATF6 was sheared in KCNH2wt+KCNH2A561V group compared with control group. Furthermore, A561V-KCNH2 mutation leading to the accumulation of the immature form of KCNH2 (135 kDa bands) in ER, resulting in the reduction of the ratio of 155 kDa/135 kDa. In addition, the abundance of UPR-related proteins in the KCNH2A561V group was higher compared with the KCNH2wt+KCNH2A561V group. The 'cysteine biosynthetic activity' of GO:0019344 process and the 'positive regulation of cytoplasmic translation activity' of GO:2000767 process in the KCNH2A561V group were higher compared with the KCNH2wt+KCNH2A561V group. Hence, co-expression of wild-type and A561V mutant KCNH2 in 293 cells activated the UPR process, which led to the inhibition of protein translation and synthesis, in turn inhibiting the expression of KCNH2. These results provided a theoretical basis for clinical treatment of Long QT syndrome.
650    12
$a transkripční faktor ATF6 $x genetika $x metabolismus $7 D051702
650    _2
$a endoplazmatické retikulum $x metabolismus $7 D004721
650    _2
$a mutace $7 D009154
650    12
$a proteomika $7 D040901
650    _2
$a signální dráha UPR $x genetika $7 D056811
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tan, L.
700    1_
$a Chen, Ding-Shinn $7 _gn020018379
700    1_
$a Wang, X.
700    1_
$a Liu, J.
700    1_
$a Huang, X.
700    1_
$a Wang, Y.
700    1_
$a Huang, S.
700    1_
$a Mao, F.
700    1_
$a Lian, J.
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 72, č. 5 (2023), s. 621-631
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38015761 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20231215 $b ABA008
991    __
$a 20250502124224 $b ABA008
999    __
$a ok $b bmc $g 2255290 $s 1206997
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 72 $c 5 $d 621-631 $e 2023Nov28 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
LZP    __
$b NLK116 $a Pubmed-20231215

Find record

Citation metrics

Archiving options